TSVT (2seventy bio) Risk Assessment

View and export this data going back to 2021. Start your Free Trial

What is 2seventy bio Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of 2seventy bio is: High Risk: High uncertainty.

Competitive Comparison of 2seventy bio's Risk Assessment

For the Biotechnology subindustry, 2seventy bio's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

2seventy bio's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 2seventy bio's Risk Assessment distribution charts can be found below:

* The bar in red indicates where 2seventy bio's Risk Assessment falls into.

2seventy bio (NAS:TSVT) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

2seventy bio Risk Assessment Related Terms

Thank you for viewing the detailed overview of 2seventy bio's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

2seventy bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2seventy bio Inc (NAS:TSVT) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

60 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.2seventybio.com

2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.

Executives

Marcela V. Maus	director	16 RICHMOND CIRCLE, LEXINGTON MA 02421
Nick Leschly	director, officer: President and CEO	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Baird William D Iii	officer: Chief Financial Officer	C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Philip D Gregory	officer: Chief Scientific Officer	POINT RICHMOND TECH CENTER II, 501 CANAL BOULEVARD SUITE A100, RICHMOND CA 94804
Kynam Capital Management, Lp	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Kynam Capital Management Gp, Llc	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Kynam Global Healthcare Master Fund, Lp	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Kynam Fund Gp, Llc	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Yue Tang	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Nicola Heffron	officer: Chief Operating Officer	2SEVENTY BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Daniel Lynch	director
Denice Torres	director	3 RABBIT RUN DRIVE, NEW HOPE PA 18938
Sarah Js Glickman	director	60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Ramy Ibrahim	director	C/O SURFACE ONCOLOGY, 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
William R. Sellers	director	C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142